Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
SILO PHARMA INC (SILO)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.29-3.01%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for SILO yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Execute stock repurchase program up to $1 million | The company has a stock repurchase program authorized for up to $1 million, showing capital return intent. | Intact | Repurchase program not executed or canceled | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative growth story, not a proven compounder: the company is loss-making, risk is high, and management execution is rated volatile. The thesis is in a watch state, with recent financial performance below its industry cohort but not newly broken.
SILO trades at a 24.55% premium to peers, while the model has low confidence and points to optionality, meaning potential future projects appear to support part of the valuation. The expectations gap is 2.68, but the evidence does not spell out precisely what the market assumes; the snapshot labels the valuation as expensive and that pricing as unjustified.
Near term, the company has elevated risk of missing next-quarter earnings, and its loss-making profile gives little evidence of durable earnings quality. Management has announced a capital raise with up to $11.7 million in potential gross proceeds, regained Nasdaq minimum bid-price compliance, and cited progress on SPC-15 and QwikAgents, though delivery evidence for the development work is limited.
Over the multi-year view, the thesis hinges on whether clinical and AI platform development produces concrete progress and whether new capital supports execution without worsening financing concerns. Near term, weakening jobs data could weigh on cyclical names, while continued strength or weakness among healthcare bellwethers could either sustain or fade the sector tailwind.
For the next 1 to 3 years, SILO remains a fragile, speculative thesis: sector support and project optionality are balanced by losses, high risk, volatile management, and limited evidence of execution. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Silo Pharma is advancing its Nasdaq listing compliance, which supports its market presence. |
| Recovered |
| Loss of Nasdaq listing compliance |
Compliance regained (qualitative) SILO regained Nasdaq bid price compliance in June 2026. No recent news indicates loss of listing status. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Advance clinical pipeline of psychedelic therapies | Its focus on novel psychedelic therapies targets unmet mental health needs. | Improving | Pipeline development stalls or regulatory setbacks occur | Qualitative progress: 2 IP acquisitions, 1 patent allowance Recent IP acquisitions and Canadian patent allowance for SPC-15 indicate continued clinical and platform development progress. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-16.80 → $-16.80 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-16.80 | $72,000 | 1 / 1 |
| 2026-07-25 | $-16.80 | $72,000 | 1 / 1 |
| 2026-07-26 | $-16.80 | $72,000 | 1 / 1 |
| 2026-07-27 | $-16.80 | $72,000 | 1 / 1 |
| 2026-07-28 | $-16.80 | $72,000 | 1 / 1 |
| 2026-07-29 | $-16.80 | $72,000 | 1 / 1 |
| 2026-07-30 | $-16.80 | $72,000 | 1 / 1 |
| 2026-07-31 | $-16.80 | $72,000 | 1 / 1 |
| 2026-08-01 | $-16.80 | $72,000 | 1 / 1 |
| 2026-08-02 | $-16.80 | $72,000 | 1 / 1 |
| 2026-08-03 | $-16.80 | $72,000 | 1 / 1 |
| 2026-08-04 | $-16.80 | $72,000 | 1 / 1 |
| 2026-08-05 | $-16.80 | $72,000 | 1 / 1 |
| 2026-08-06 | $-16.80 | $72,000 | 1 / 1 |
| 2026-08-08 | $-16.80 | $72,000 | 1 / 1 |
| 2026-08-09 | $-16.80 | $72,000 | 1 / 1 |
| 2026-08-10 | $-16.80 | $72,000 | 1 / 1 |
| 2026-08-12 | $-16.80 | $72,000 | 1 / 1 |
| 2026-08-13 | $-16.80 | $72,000 | 1 / 1 |
| 2026-08-14 | $-16.80 | $72,000 | 1 / 1 |
| 2026-08-15 | $-16.80 | $72,000 | 1 / 1 |
| 2026-08-16 | $-16.80 | $72,000 | 1 / 1 |
| 2026-08-17 | $-16.80 | $72,000 | 1 / 1 |
| 2026-08-18 | $-16.80 | $72,000 | 1 / 1 |
| 2026-08-19 | $-16.80 | $72,000 | 1 / 1 |
| 2026-08-20 | $-16.80 | $72,000 | 1 / 1 |
| 2026-08-21 | $-16.80 | $72,000 | 1 / 1 |
| 2026-08-22 | $-16.80 | $72,000 | 1 / 1 |
| 2026-08-23 | $-16.80 | $72,000 | 1 / 1 |
| 2026-08-24 | $-16.80 | $72,000 | 1 / 1 |
| 2026-08-25 | $-16.80 | $72,000 | 1 / 1 |
| 2026-08-26 | $-16.80 | $72,000 | 1 / 1 |
| 2026-08-27 | $-16.80 | $72,000 | 1 / 1 |
| 2026-08-28 | $-16.80 | $72,000 | 1 / 1 |
| 2026-08-29 | $-16.80 | $72,000 | 1 / 1 |
| 2026-08-30 | $-16.80 | $72,000 | 1 / 1 |
| 2026-08-31 | $-16.80 | $72,000 | 1 / 1 |
| 2026-09-01 | $-16.80 | $72,000 | 1 / 1 |
| 2026-09-02 | $-16.80 | $72,000 | 1 / 1 |
| 2026-09-03 | $-16.80 | $72,000 | 1 / 1 |
| 2026-09-04 | $-16.80 | $72,000 | 1 / 1 |
| 2026-09-05 | $-16.80 | $72,000 | 1 / 1 |
| 2026-09-06 | $-16.80 | $72,000 | 1 / 1 |
| 2026-09-07 | $-16.80 | $72,000 | 1 / 1 |
| 2026-09-08 | $-16.80 | $72,000 | 1 / 1 |
| 2026-09-09 | $-16.80 | $72,000 | 1 / 1 |
| 2026-09-10 | $-16.80 | $72,000 | 1 / 1 |
| 2026-09-11 | $-16.80 | $72,000 | 1 / 1 |
| 2026-09-12 | $-16.80 | $72,000 | 1 / 1 |
| 2026-09-13 | $-16.80 | $72,000 | 1 / 1 |
| 2026-09-14 | $-16.80 | $72,000 | 1 / 1 |
| 2026-09-15 | $-16.80 | $72,000 | 1 / 1 |
| 2026-09-16 | $-16.80 | $72,000 | 1 / 1 |
| 2026-09-17 | $-16.80 | $72,000 | 1 / 1 |
| 2026-09-18 | $-16.80 | $72,000 | 1 / 1 |
| 2026-09-19 | $-16.80 | $72,000 | 1 / 1 |
| 2026-09-20 | $-16.80 | $72,000 | 1 / 1 |
| 2026-09-21 | $-16.80 | $72,000 | 1 / 1 |
| 2026-09-22 | $-16.80 | $72,000 | 1 / 1 |
| 2026-09-23 | $-16.80 | $72,000 | 1 / 1 |
| 2026-09-24 | $-16.80 | $72,000 | 1 / 1 |
| 2026-09-25 | $-16.80 | $72,000 | 1 / 1 |
| 2026-09-26 | $-16.80 | $72,000 | 1 / 1 |
| 2026-09-27 | $-16.80 | $72,000 | 1 / 1 |
| 2026-09-28 | $-16.80 | $72,000 | 1 / 1 |
| 2026-09-29 | $-16.80 | $72,000 | 1 / 1 |
| 2026-09-30 | $-16.80 | $72,000 | 1 / 1 |
| 2026-10-01 | $-16.80 | $72,000 | 1 / 1 |
| 2026-10-02 | $-16.80 | $72,000 | 1 / 1 |
| 2026-10-03 | $-16.80 | $72,000 | 1 / 1 |
| 2026-10-04 | $-16.80 | $72,000 | 1 / 1 |
| 2026-10-05 | $-16.80 | $72,000 | 1 / 1 |
| 2026-10-06 | $-16.80 | $72,000 | 1 / 1 |
| 2026-10-07 | $-16.80 | $72,000 | 1 / 1 |
| 2026-10-08 | $-16.80 | $72,000 | 1 / 1 |
| 2026-10-09 | $-16.80 | $72,000 | 1 / 1 |
| 2026-10-10 | $-16.80 | $72,000 | 1 / 1 |
| 2026-10-11 | $-16.80 | $72,000 | 1 / 1 |
| 2026-10-12 | $-16.80 | $72,000 | 1 / 1 |
| 2026-10-13 | $-16.80 | $72,000 | 1 / 1 |
| 2026-10-14 | $-16.80 | $72,000 | 1 / 1 |
| 2026-10-15 | $-16.80 | $72,000 | 1 / 1 |
| 2026-10-16 | $-16.80 | $72,000 | 1 / 1 |
| 2026-10-17 | $-16.80 | $72,000 | 1 / 1 |
| 2026-10-18 | $-16.80 | $72,000 | 1 / 1 |
| 2026-10-19 | $-16.80 | $72,000 | 1 / 1 |
| 2026-10-20 | $-16.80 | $72,000 | 1 / 1 |
| 2026-10-21 | $-16.80 | $72,000 | 1 / 1 |
| 2026-10-22 | $-16.80 | $72,000 | 1 / 1 |
| 2026-10-23 | $-16.80 | $72,000 | 1 / 1 |
| 2026-10-24 | $-16.80 | $72,000 | 1 / 1 |
| 2026-10-25 | $-16.80 | $72,000 | 1 / 1 |
| 2026-10-26 | $-16.80 | $72,000 | 1 / 1 |
| 2026-10-27 | $-16.80 | $72,000 | 1 / 1 |
| 2026-10-28 | $-16.80 | $72,000 | 1 / 1 |
| 2026-10-29 | $-16.80 | $72,000 | 1 / 1 |
| 2026-10-30 | $-16.80 | $72,000 | 1 / 1 |
| 2026-10-31 | $-16.80 | $72,000 | 1 / 1 |
| 2026-11-01 | $-16.80 | $72,000 | 1 / 1 |
| 2026-11-02 | $-16.80 | $72,000 | 1 / 1 |
| 2026-11-03 | $-16.80 | $72,000 | 1 / 1 |
| 2026-11-04 | $-16.80 | $72,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Monthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
1 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.